Back

Comparative clinical outcomes on renal function and mortality of uricosuric agents versus xanthine oxidase inhibitors in patients with hyperuricemia and cardiovascular risks

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Using big data to drive cardiovascular innovations Big Data analysis ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Atsuyuki Wada

Omi Medical Centre, Kusatsu (Japan)

5 More presentations in this session

Presentation thumbnail
The continuity of care in primary care improves prognosis in patients referred to a cardiology department
Doctor J. Gonzalez Juanatey (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Development and implementation of a heart failure dashboard for England: nationwide analysis of 1.4 million primary and secondary health care records
Professor C. Gale (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Development and validation of a nomogram model for all-cause mortality risk in patients with acute myocardial infarction complicated by impaired activity daily living
Doctor Y. Zhang (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial
Doctor F. Fusco (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Clinical profiles and temporal trends of 37,741 cardiovascular hospitalizations in greece over 13 years: initial insights from the CardioMining-AI nationwide database
Doctor A. Samaras (Thessaloniki, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Using big data to drive cardiovascular innovations
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Mildly decreased egfr modifies the association between uric acid and risk of kidney function decline: a 5-year population-based cohort study
thumbnail
Congress Presentation
Sacubitril/Allisartan in hyperuricemia
thumbnail
Congress Presentation
Impact of changes in serum uric acid levels on clinical outcomes in patients with asymptomatic hyperuricemia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources